Nicolas Ajkay1, Neal Bhutiani1, Bin Huang2, Quan Chen3, Jeffrey D Howard1, Thomas C Tucker4, Charles R Scoggins1, Kelly M McMasters1, Hiram C Polk5. 1. The Hiram C Polk Jr Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, KY. 2. Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY. 3. Biostatistics and Bioinformatics Shared Resource Facility, Markey Cancer Center, University of Kentucky, Lexington, KY. 4. Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington, KY. 5. The Hiram C Polk Jr Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, KY. Electronic address: Hcpolk01@louisville.edu.
Abstract
BACKGROUND: In January 2014, Kentucky expanded Medicaid coverage to include all individuals and families with incomes up to 33% above the federal poverty line. This study evaluated the early impact of Medicaid expansion on some aspects of the quality of breast cancer care in Kentucky. STUDY DESIGN: The Kentucky Cancer Registry was queried for all women aged 20 to 64 years diagnosed with breast cancer between 2011 and 2016. Demographic, tumor, and treatment characteristics were assessed for each year during this interval. To evaluate the association between Medicaid expansion and these parameters, these variables, along with quality metrics deriving from said variables, were compared for the years 2011 to 2013 (pre) and the years 2014 to 2016 (post). RESULTS: Of 13,625 women with breast cancer, 11,915 (59.5%) were diagnosed and treated from 2011 to 2013, and 8,127 (40.5%) were diagnosed and treated from 2014 to 2016. After Medicaid expansion, fewer patients were uninsured (3.7% post vs 1.0% pre) and more were covered by Medicaid (15.9% post vs 10.9% pre) (p < 0.001). There was increased diagnosis of early stage (I and II) breast cancer (p = 0.002) and an increasing proportion of women undergoing breast-conservation therapy (p < 0.001). Time from diagnosis to operation increased (p < 0.001), time from operation to chemotherapy remained unchanged (p = 0.26) and time from operation to radiation decreased (p < 0.001). CONCLUSIONS: The expansion of Kentucky Medicaid in 2014 has been associated with earlier diagnosis and somewhat improved quality of breast cancer care, despite a stable disease incidence. Additional improvements in treatment expediency will require improvements in patient outreach and healthcare infrastructure.
BACKGROUND: In January 2014, Kentucky expanded Medicaid coverage to include all individuals and families with incomes up to 33% above the federal poverty line. This study evaluated the early impact of Medicaid expansion on some aspects of the quality of breast cancer care in Kentucky. STUDY DESIGN: The Kentucky Cancer Registry was queried for all women aged 20 to 64 years diagnosed with breast cancer between 2011 and 2016. Demographic, tumor, and treatment characteristics were assessed for each year during this interval. To evaluate the association between Medicaid expansion and these parameters, these variables, along with quality metrics deriving from said variables, were compared for the years 2011 to 2013 (pre) and the years 2014 to 2016 (post). RESULTS: Of 13,625 women with breast cancer, 11,915 (59.5%) were diagnosed and treated from 2011 to 2013, and 8,127 (40.5%) were diagnosed and treated from 2014 to 2016. After Medicaid expansion, fewer patients were uninsured (3.7% post vs 1.0% pre) and more were covered by Medicaid (15.9% post vs 10.9% pre) (p < 0.001). There was increased diagnosis of early stage (I and II) breast cancer (p = 0.002) and an increasing proportion of women undergoing breast-conservation therapy (p < 0.001). Time from diagnosis to operation increased (p < 0.001), time from operation to chemotherapy remained unchanged (p = 0.26) and time from operation to radiation decreased (p < 0.001). CONCLUSIONS: The expansion of Kentucky Medicaid in 2014 has been associated with earlier diagnosis and somewhat improved quality of breast cancer care, despite a stable disease incidence. Additional improvements in treatment expediency will require improvements in patient outreach and healthcare infrastructure.
Authors: David A Barrington; Jennifer A Sinnott; Corinne Calo; David E Cohn; Casey M Cosgrove; Ashley S Felix Journal: Gynecol Oncol Date: 2020-06-09 Impact factor: 5.482
Authors: Tong Gan; Heather F Sinner; Samuel C Walling; Quan Chen; Bin Huang; Tom C Tucker; Jitesh A Patel; B Mark Evers; Avinash S Bhakta Journal: J Am Coll Surg Date: 2019-02-22 Impact factor: 6.113
Authors: J Asher Jenkins; Schelomo Marmor; Jane Yuet Ching Hui; Heather Beckwith; Anne H Blaes; David Potter; Todd M Tuttle Journal: Breast Cancer Res Treat Date: 2021-10-29 Impact factor: 4.872
Authors: Neal Bhutiani; Adam C Hicks; Bin Huang; Quan Chen; Thomas C Tucker; Kelly M McMasters; Nicolás Ajkay Journal: J Surg Oncol Date: 2020-03-29 Impact factor: 2.885